The United States is facing increasing competition in the global technology and biotechnology sectors, particularly from China. While the U.S. has 690 privately held tech companies valued at $2.53 trillion, compared to the European Union's 107 firms worth $333.4 billion, China is rapidly advancing, especially in biotech. U.S. venture capitalists and Western pharmaceutical companies, including Pfizer and Bayer, are seeking billion-dollar deals to acquire Chinese biotech innovations, despite warnings from Congress and the White House that investing in Chinese biotech could backfire. The National Security Commission on Emerging Biotechnology (NSCEB) has issued recommendations to support the American biotech sector, including the creation of an Independence Investment Fund to counter adversarial capital risk. America First measures on immigration, university funding, tariffs, and energy are influencing the U.S. tech landscape. Meanwhile, Europe's inability to create more big tech firms and unicorns has contributed to its economic growth gap with the U.S.